Canagliflozin is FDA approved for the indication of preservation of renal function due to highly significant delayed renal deterioration in patients with a lower baseline eGFR (56 mL/min/1.73 m 2 ) with macroalbuminuria.
← all excerpts
Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM.
1
—
—